136 related articles for article (PubMed ID: 38330738)
1. Anlotinib suppressed tumor cell proliferation and migration in hypopharyngeal carcinoma.
Song H; Song Q; Zhao X; Yang Y; Mou Y; Li Y; Song X
Braz J Otorhinolaryngol; 2024; 90(2):101397. PubMed ID: 38330738
[TBL] [Abstract][Full Text] [Related]
2. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
[TBL] [Abstract][Full Text] [Related]
3. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
[TBL] [Abstract][Full Text] [Related]
4. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S
Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
[TBL] [Abstract][Full Text] [Related]
6. Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway.
Xu P; Wang H; Pan H; Chen J; Deng C
Cancer Chemother Pharmacol; 2022 Feb; 89(2):183-196. PubMed ID: 34997858
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib Inhibits Ovarian Cancer and Enhances Cisplatinum Sensitivity
Xu X; Wang Q; Shen L; Shen Y; Liu H; Liu Y; Yang Z; Hoffman RM; Feng W
Anticancer Res; 2024 Apr; 44(4):1399-1407. PubMed ID: 38538004
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis.
Zhu Y; Wang X; Chen Z; Zhou L; Di X; Fan P; He Z
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614964
[TBL] [Abstract][Full Text] [Related]
9. Anlotinib inhibits the progress of colorectal cancer cells by antagonizing VEGFR/JAK2/STAT3 axis.
Jia ZX; Zhang Z; Li Z; Li A; Xie YN; Wu HJ; Yang ZB; Zhang HM; Zhang XM
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2331-2343. PubMed ID: 33755971
[TBL] [Abstract][Full Text] [Related]
10. Blocking long noncoding RNA MALAT1 restrained the development of laryngeal and hypopharyngeal carcinoma.
Xu E; Liang X; Ji Z; Zhao S; Li L; Lang J
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):611-621. PubMed ID: 31792655
[TBL] [Abstract][Full Text] [Related]
11. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of long non-coding RNA MALAT1 elevates microRNA-429 to suppress the progression of hypopharyngeal squamous cell carcinoma by reducing ZEB1.
Liu X; Zhao W; Wang X
Life Sci; 2020 Dec; 262():118480. PubMed ID: 32980391
[TBL] [Abstract][Full Text] [Related]
13. Anlotinib suppresses proliferation, migration, and immune escape of gastric cancer cells by activating the cGAS-STING/IFN-β pathway.
Yuan M; Guo XL; Chen JH; He Y; Liu ZQ; Zhang HP; Ren J; Xu Q
Neoplasma; 2022 Jul; 69(4):807-819. PubMed ID: 35471977
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting PI3K/Akt and MAPK/ERK pathways leads to an enhanced antitumor effect on human hypopharyngeal squamous cell carcinoma.
Peng X; Liu Y; Zhu S; Peng X; Li H; Jiao W; Lin P; Zhang Z; Qiu Y; Jin M; Wang R; Kong D
J Cancer Res Clin Oncol; 2019 Dec; 145(12):2921-2936. PubMed ID: 31620898
[TBL] [Abstract][Full Text] [Related]
15. Nimesulide inhibited the growth of hypopharyngeal carcinoma cells via suppressing Survivin expression.
Jia-Jun T; Su-Mei L; Liang Y; Ju-Ke M; Ya-Kui M; Hai-Bo W; Wei X
Head Neck Oncol; 2012 Mar; 4():7. PubMed ID: 22453101
[TBL] [Abstract][Full Text] [Related]
16. [miR-140-5p affects the migration and invasion of hypopharyngeal carcinoma cells by downregulating ADAM10 expression].
Jing P; Sa N; Xu W
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Mar; 51(3):189-96. PubMed ID: 27033573
[TBL] [Abstract][Full Text] [Related]
17. NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib.
Gu G; Hu C; Hui K; Chen T; Zhang H; Jiang X
Aging (Albany NY); 2021 May; 13(10):13941-13953. PubMed ID: 33982669
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer.
Yang L; Zhou X; Sun J; Lei Q; Wang Q; Pan D; Ding M; Ding Y
Cell Death Dis; 2020 Sep; 11(9):766. PubMed ID: 32943607
[TBL] [Abstract][Full Text] [Related]
19. Effects of HPV-16 infection on hypopharyngeal squamous cell carcinoma and FaDu cells.
Lu W; Feng L; Li P; Wang Y; Du Y; Chen X; Wu S; Zhao G; Lou W
Oncol Rep; 2016 Jan; 35(1):99-106. PubMed ID: 26497405
[TBL] [Abstract][Full Text] [Related]
20. In vitro studies of H520 cell cycle and apoptosis by anlotinib combined with radiotherapy.
Guo L; Zhang L; Guan Y; Li Y; Zhang C; Guo Q
Thorac Cancer; 2021 Mar; 12(5):593-602. PubMed ID: 33438349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
